MX2019005504A - Potenciadores de bmp. - Google Patents

Potenciadores de bmp.

Info

Publication number
MX2019005504A
MX2019005504A MX2019005504A MX2019005504A MX2019005504A MX 2019005504 A MX2019005504 A MX 2019005504A MX 2019005504 A MX2019005504 A MX 2019005504A MX 2019005504 A MX2019005504 A MX 2019005504A MX 2019005504 A MX2019005504 A MX 2019005504A
Authority
MX
Mexico
Prior art keywords
potentiators
bmp
formula
methods
compounds
Prior art date
Application number
MX2019005504A
Other languages
English (en)
Spanish (es)
Inventor
Rothman Deborah
Ding Jian
Helene Larraufie Marie-
Savage Nik
Wang Shaowen
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of MX2019005504A publication Critical patent/MX2019005504A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
    • C07D498/18—Bridged systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/436—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e.g. rapamycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/453—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with oxygen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/08—Bridged systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Rheumatology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Pain & Pain Management (AREA)
  • Immunology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Obesity (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Pulmonology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Thiazole And Isothizaole Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
MX2019005504A 2016-11-10 2017-11-08 Potenciadores de bmp. MX2019005504A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201662420535P 2016-11-10 2016-11-10
PCT/IB2017/056991 WO2018087677A1 (en) 2016-11-10 2017-11-08 Bmp potentiators

Publications (1)

Publication Number Publication Date
MX2019005504A true MX2019005504A (es) 2019-08-12

Family

ID=60569967

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2019005504A MX2019005504A (es) 2016-11-10 2017-11-08 Potenciadores de bmp.

Country Status (15)

Country Link
US (2) US10259827B2 (https=)
EP (1) EP3538531A1 (https=)
JP (1) JP2019534302A (https=)
KR (1) KR20190075120A (https=)
CN (1) CN109923118A (https=)
AR (1) AR110163A1 (https=)
AU (1) AU2017357719A1 (https=)
BR (1) BR112019009404A2 (https=)
CA (1) CA3043575A1 (https=)
EA (1) EA201991141A1 (https=)
MX (1) MX2019005504A (https=)
RU (1) RU2019117548A (https=)
TW (1) TW201821076A (https=)
UY (1) UY37477A (https=)
WO (1) WO2018087677A1 (https=)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2021008824A (es) * 2019-01-23 2021-10-13 Univ Johns Hopkins Análogos no inmunosupresores de tacrolimus (fk506) y uso de los mismos.
WO2026059989A1 (en) * 2024-09-10 2026-03-19 Montara Therapeutics, Inc. Peripheral blockers for central nervous system-selective drug activity
WO2026060005A1 (en) * 2024-09-10 2026-03-19 Montara Therapeutics, Inc. Macrocyclic blockers for use in the reduction of peripheral side effects due to everolimus therapy

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1989005304A1 (en) 1987-12-09 1989-06-15 Fisons Plc Macrocyclic compounds
EP0378318A1 (en) 1989-01-11 1990-07-18 Merck & Co. Inc. Process for synthesis of FK-506 and tricarbonyl intermediates
GR1001225B (el) 1989-09-14 1993-06-30 Fisons Plc Νέαι μακροκυκλικαί ενώσεις και νέα μέ?οδος χρήσεως τους.
GB9014136D0 (en) * 1990-06-25 1990-08-15 Fujisawa Pharmaceutical Co Tricyclo compounds,a process for their production and a pharmaceutical composition containing the same
DE4028677A1 (de) * 1990-09-10 1992-03-12 Sandoz Ag Heteroatome enthaltende, tricyclische verbindungen, verfahren zu ihrer herstellung und ihre verwendung
DE4028676A1 (de) * 1990-09-10 1992-03-12 Sandoz Ag Heteroatome enthaltende, tricyclische verbindungen, verfahren zu ihrer herstellung und ihre verwendung
DE4028664A1 (de) * 1990-09-10 1992-03-12 Sandoz Ag Heteroatome enthaltende, tricyclische verbindungen, verfahren zu ihrer herstellung und ihre verwendung
DE4028666A1 (de) * 1990-09-10 1992-03-12 Sandoz Ag Heteroatome enthaltende, tricyclische verbindungen, verfahren zu ihrer herstellung und ihre verwendung
DE4028675A1 (de) * 1990-09-10 1992-03-12 Sandoz Ag Heteroatome enthaltende, tricyclische verbindungen, verfahren zu ihrer herstellung und ihre verwendung
CA2071332A1 (en) * 1991-06-25 1992-12-26 Laszlo R. Treiber C-21 hydroxylated fk-506 antagonist
GB9202196D0 (en) 1992-02-01 1992-03-18 Fisons Plc Method of treatment
US5284877A (en) * 1992-06-12 1994-02-08 Merck & Co., Inc. Alkyl and alkenyl macrolides having immunosuppressive activity
GB9218027D0 (en) 1992-08-25 1992-10-14 Fisons Plc Novel method of treatment
GB9218597D0 (en) 1992-08-25 1992-10-14 Fisons Plc Novel method of treatment
US7109317B1 (en) * 1998-11-06 2006-09-19 President And Fellows Of Harvard College FK506-based regulation of biological events
WO2000058318A1 (en) * 1999-03-31 2000-10-05 Abbott Laboratories Phosphate containing macrocyclic immunomodulators
US6569867B2 (en) 1999-10-01 2003-05-27 Kosan Biosciences, Inc. Polyketide derivatives
CA2407259A1 (en) 2000-05-17 2001-11-22 Chaitan Khosla Polyketide derivatives
JP2007524596A (ja) 2003-02-28 2007-08-30 トランスフォーム・ファーマシューティカルズ・インコーポレイテッド 共結晶医薬組成物
EP1838316A4 (en) * 2005-01-20 2012-01-25 Array Biopharma Inc MACROCYCLIC ANALOGUES USEFUL FOR THE TREATMENT OF IMMUNOREGULATION DISORDERS AND RESPIRATORY DISEASES
WO2012047762A2 (en) 2010-10-08 2012-04-12 Amplyx Pharmaceuticals, Inc. Antifungal agents
EP3094324A4 (en) 2014-01-13 2017-02-22 Amplyx Pharmaceuticals, Inc. Antifungal compounds

Also Published As

Publication number Publication date
UY37477A (es) 2018-06-29
EP3538531A1 (en) 2019-09-18
US20180127436A1 (en) 2018-05-10
KR20190075120A (ko) 2019-06-28
US20190194227A1 (en) 2019-06-27
BR112019009404A2 (pt) 2019-07-30
AU2017357719A1 (en) 2019-05-16
CA3043575A1 (en) 2018-05-17
CN109923118A (zh) 2019-06-21
AR110163A1 (es) 2019-02-27
JP2019534302A (ja) 2019-11-28
TW201821076A (zh) 2018-06-16
WO2018087677A1 (en) 2018-05-17
RU2019117548A (ru) 2020-12-10
US10259827B2 (en) 2019-04-16
EA201991141A1 (ru) 2019-10-31

Similar Documents

Publication Publication Date Title
WO2016011390A8 (en) Irak4 inhibiting agents
MA39749A (fr) Dérivés de pipéridine-dione
PH12017501523A1 (en) Selective bace1 inhibitors
GEP20186933B (en) Substituted dihydroisoquinoline compounds
PH12015502031B1 (en) Tetrahydropyrrolothiazine compounds
TN2019000211A1 (en) Antitumoral compounds
EA201790627A1 (ru) СТИМУЛЯТОРЫ рГЦ
SA519402288B1 (ar) مركب بيريميدين واستخداماته الصيدلانية
PH12019501022A1 (en) Pyrazolopyrimidine compounds and methods of use thereof
MX2016009794A (es) Derivado de sulfonamida heterociclico y medicina que comprende el mismo.
JOP20190163B1 (ar) منشط nrf2
MX369506B (es) Composiciones de sales metálicas.
MX382092B (es) Compuestos heterocíclicos para el tratamiento de enfermedades.
AU2017257755A1 (en) Benzoylglycine derivatives and methods of making and using same
PH12019500370A1 (en) Triazolopyrazinone derivative useful as a human pde1 inhibitor
NZ732704A (en) Quinoline carboxamides for use in the treatment of leukemia
NZ730816A (en) Quinoline carboxamides for use in the treatment of multiple myeloma
AU2016330503A8 (en) Therapeutic compounds and methods of use thereof
MX2019005504A (es) Potenciadores de bmp.
PH12016502592A1 (en) 3'-substituted-abscisic acid derivatives
MY180727A (en) Tetrahydrofurane-fused aminohydrothiazine derivatives which are useful in the treatment of alzeimer?s disease
MX387349B (es) Compuesto que inhibe la formación de complejo de c-myc/max/adn.
WO2016025473A3 (en) Synthesis of tetracyclic flavonoids
PH12019550212B1 (en) Process for the preparation of pirlindole enantiomers and its salts
MY174415A (en) Salt form, crystal form and intermediate of 1,2,5-thiadiazolidine-1,1-dioxide and preparation method thereof